Scientists at the University of Cincinnati have found a way that muscles can take in sugar without insulin, a discovery that could open a new direction in diabetes research. The team identified a previously unknown pathway in skeletal muscle, and the findings were published on 19 November 2026.
Key takeaways
- Researchers at the University of Cincinnati College of Medicine found that skeletal muscle can absorb glucose without insulin through a pathway called mSGLT.
- The study was published in Communications Biology on 19 November 2026, and the work was led by the laboratory of Judith A. Heiny, PhD, with Natalie J. Norman, PhD, as first author.
- mSGLT is a sodium-linked glucose transporter that shares properties with SGLT2, the kidney transporter targeted by diabetes drugs such as Jardiance.
- The discovery is relevant to diabetes, high blood sugar and insulin resistance, but the study was carried out in mice.
- This is early research, not a treatment. The next step is to identify the specific protein and gene behind the pathway.
What the researchers found
For decades, the standard explanation of how muscles absorb sugar has centred on insulin. After a meal, blood sugar rises, the pancreas releases insulin, and insulin signals muscle cells to take glucose in from the blood. That process is essential for keeping blood sugar in a healthy range, and it is the process that breaks down in diabetes.
The Cincinnati team found that skeletal muscle has another route. In their experiments, muscle tissue absorbed glucose even when insulin was not involved. The pathway depends on a sodium-linked glucose transporter, which the researchers have called mSGLT. Sodium-linked transporters use the movement of sodium across a cell membrane to carry glucose along with it, a mechanism already well known in other parts of the body.
The study was published in Communications Biology on 19 November 2026. The research came from the laboratory of Judith A. Heiny, PhD, and the first author was Natalie J. Norman, PhD. The publication date and the journal give the finding a clear, checkable record, which matters because the result challenges a long-standing assumption about how muscle handles glucose.
What is mSGLT?
mSGLT stands for muscle sodium-linked glucose transporter. It is a pathway in skeletal muscle that moves glucose into muscle cells using sodium, rather than relying on the insulin signal that normally triggers glucose uptake. The researchers describe it as previously unknown, meaning it had not been identified as a route for glucose into muscle before this study.
Why the SGLT2 connection matters
The new pathway shares properties with SGLT2, a transporter found in the kidneys. SGLT2 is already a familiar target in diabetes care: drugs such as Jardiance block SGLT2 in the kidney, which makes the body pass more glucose out in urine and lowers blood sugar. The fact that mSGLT resembles SGLT2 is one reason the discovery has drawn attention. Researchers already know a great deal about this family of transporters, and that existing knowledge could help them study the muscle version more quickly.
It is important to be precise here. Sharing properties with SGLT2 does not mean that existing SGLT2 drugs will work on mSGLT, and it does not mean that a new drug is close. It means scientists have a useful starting point for asking how the muscle transporter works and whether it can be influenced safely.
Why this matters for diabetes
Diabetes affects hundreds of millions of people around the world, and its core problem is blood sugar that stays too high. In type 1 diabetes, the body makes little or no insulin. In type 2 diabetes, which is far more common, the body still makes insulin but muscle and other tissues respond to it poorly, a condition called insulin resistance. When muscle, the body's largest consumer of glucose, stops responding well to insulin, blood sugar climbs.
A pathway that lets muscle absorb glucose without insulin could, in theory, offer a way around insulin resistance. If scientists can learn how mSGLT is switched on and off, they might one day find a way to help muscle take in more glucose even when insulin signalling is weak. That is a long way from a medicine, but it is a new direction, and new directions are valuable in a field where existing treatments do not work well enough for many patients.
The finding is also relevant to hyperglycemia, the medical term for high blood sugar, and to the broader study of how the body manages energy. Muscle is not a minor player in blood sugar control: it is one of the main tissues that clears glucose from the blood after eating. A second route into muscle changes the picture of how that system works.
What this is not
Honesty about the limits of this study is essential. The research was carried out in mice, not in people. Findings in mice often point in a useful direction, but they do not always translate to humans, and the human version of this pathway still needs to be confirmed. Nobody should change their diabetes treatment, diet or medication on the basis of this news.
The study also does not identify the specific protein or gene responsible for mSGLT. That is the next step the researchers have set for themselves, and it is a necessary one: without knowing the exact protein, scientists cannot design a drug to target it, and they cannot be sure how the pathway behaves in different conditions.
There is no treatment, no drug and no clinical trial attached to this discovery yet. News about early research is often reported as if a cure is around the corner, and that is misleading. The honest summary is that scientists have found a new piece of the puzzle, and the puzzle is still far from finished.
What happens next
The immediate next step is identifying the specific protein and gene behind mSGLT. Once that is known, researchers can study when the pathway is active, what switches it on, and whether it behaves the same way in human muscle as it does in mice. That work will take time, and it will need to be repeated and confirmed by other laboratories before it can be treated as established science.
If the pathway is confirmed in humans, the longer-term question is whether it can be targeted safely. Any future drug would need to increase glucose uptake in muscle without disturbing the balance of sodium and glucose elsewhere in the body. That is a demanding standard, and it is why the path from a laboratory finding to a medicine usually takes many years.
For now, the value of the discovery is scientific. It gives diabetes researchers a new mechanism to study, a new question to ask, and a possible new target for the future. Patients and doctors should watch for follow-up studies rather than expecting quick changes to treatment.
Conclusion
The University of Cincinnati team has shown that skeletal muscle can absorb sugar without insulin through a newly identified pathway called mSGLT, a finding published in Communications Biology on 19 November 2026. The discovery is relevant to diabetes, hyperglycemia and insulin resistance, and its similarity to the kidney transporter SGLT2 gives researchers a familiar starting point. But it is early mouse research, the specific protein and gene are still unknown, and there is no treatment yet. The result is a promising new direction, not a cure, and its real test will come in the follow-up studies that are now needed.
Frequently asked questions
Can muscles really absorb sugar without insulin?
According to the new study, yes, in mice. Researchers at the University of Cincinnati found that skeletal muscle can take in glucose through a sodium-linked transporter pathway called mSGLT, without needing insulin. The finding still needs to be confirmed in humans.
Does this mean a new diabetes treatment is coming?
Not yet. This is early laboratory research in mice, and the specific protein and gene behind mSGLT have not been identified. Any future treatment based on this pathway would be many years away, if it proves possible at all.
What is the link to Jardiance?
Jardiance is a diabetes drug that targets SGLT2, a transporter in the kidneys. The newly found muscle pathway, mSGLT, shares properties with SGLT2. That similarity may help researchers study it, but it does not mean Jardiance acts on muscles or that a muscle-targeted drug already exists.
Researched with AI assistance and reviewed for accuracy.
Follow on WhatsApp
Follow Daily Tech & AI on WhatsApp for the latest tech news, AI updates and research breakthroughs: https://www.whatsapp.com/channel/0029Vb9XzdHDJ6H4TFNAl61r
Sources
- https://medicalxpress.com/news/2026-11-discovery-approach-diabetes-insulin-required.html
- https://doi.org/10.1038/s42003-026-10848-y
- Internal link: https://amjadphd.blogspot.com/2026/11/claude-riemann-hypothesis-claim.html
- Internal link: https://amjadphd.blogspot.com/2026/11/best-ai-video-generator-2026.html
Comments
Post a Comment